Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view

Int J Gynecol Cancer. 2006:16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Postmenopause*
  • Receptors, Estrogen / metabolism*
  • Tamoxifen / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Estrogen
  • Tamoxifen